BlackRock backs UK life sciences firm in latest PE round
BlackRock, the US asset manager, has taken part in a $75m Series 'C' financing for Immunocore, a UK life sciences company that works in developing treatments that use the body’s T-cell receptors to fight cancer and other diseases.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: